The 2018 Annual Meeting Scientific Program addresses state-of-the-art recent developments in autologous and allogeneic transplantation. Transplantation is viewed not as a stand-alone procedure, but as part of a complex therapeutic program that includes molecularly targeted drugs, supportive therapies, cell selection and gene-modified cell therapies. The key message is the integration across top level science, high technology (particularly cell and gene therapy) and clinical experience.

Hematopoietic stem cells
Stem cell mobilization, collection and engineering
Cell therapy / Cellular therapy
Gene therapy
New drug- and cell-based immune therapies
Non-hematopoietic stem cells
Regenerative medicine

Stem cell source
Stem cell donor
Graft-versus-host disease – preclinical and animal models
Graft-versus-host disease – clinical
Infectious complications
Early complications / Late effects and quality of life
Conditioning regimen
Minimal residual disease, tolerance, chimerism and
immune reconstitution
Paediatric issues
Experimental stem cell transplantation

Acute leukaemia
Aplastic anaemia
Autoimmune diseases
Chronic leukaemia
Haemoglobinopathy and inborn errors of metabolism
Multiple myeloma
Myelodysplastic syndromes
Solid tumors

Data management

Quality management
Regulatory issues
Sharing best practice
Medico-economics in cell transplantation

Care of the carer
Complementary therapies
Donor issues
Ethical issues
Impact of new therapies on patient care
Information and education
Outpatient developments
Palliative care
Patient safety
Psycho-social issues
Protective care
Quality of life
Standards of care
Symptom management

New combination of drugs for GVHD prophylaxis
Pharmacological aspects on combining cytotoxic drugs in pretransplant conditioning therapy
Conditioning regimens in patients with renal impairment and for aplastic anemia
Melphalan therapeutic drug monitoring in children
T-cell replete haploidentical transplant conditioning regimens
Allo HSCT for non-malignant disorders
Stem cell mobilization
Steroid resistant acute GvHD: Option of treatment
Production of GMP-grade “off the shelf” mesenchymal stromal cells
Mesenchymal stromal cells for the treatment of steroid resistant acute GvHD
CAR-T cells for the treatment of B cell malignancies
Fecal microbiota transplantation

Living and defeating cancer
Supporting young adult patients
Taking care of related donors
The psychosocial approach and integrated psychooncology